Multiple Myeloma

Thomas Urban Marron, MD, PhD, discusses primary objectives of a study examining the use of an adjuvant personalized neoantigen peptide vaccine in several malignancies.

Daratumumab appears to be safe when used as consolidation therapy in patients with multiple myeloma, even soon after autologous stem cell transplant, and the agent has also demonstrated early efficacy in the setting of very good responders.

Nina Shah, MD, discusses the management of CAR T-cell therapy–related toxicities in multiple myeloma.

In December 2020, the FDA approved selinexor in combination with the proteasome inhibitor bortezomib and dexamethasone for patients with MM who have received at least 1 prior therapy.

The rolling submission of a biologics license application to support the approval of the investigational BCMA-directed CAR T-cell therapy ciltacabtagene autoleucel for the treatment of patients with relapsed/refractory multiple myeloma has been completed.

Thomas G. Martin, MD, discusses the safety profile of bispecific T-cell engagers in multiple myeloma.

Shaji K. Kumar, MD, discusses the evolving role of venetoclax in relapsed/refractory multiple myeloma.

The FDA has approved isatuximab in combination with carfilzomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have previously received 1 to 3 lines of therapy.

The National Comprehensive Cancer Network guidelines for the management of frontline and relapsed/refractory multiple myeloma were updated to incorporate novel agents and combination strategies, providing a wide range of category 1 recommended therapies for patients.

The European Commission has granted conditional marketing authorization for selinexor for use in combination with dexamethasone for the treatment of adult patients with multiple myeloma who have previously received at least 4 therapies and whose disease is refractory to at least 2 proteasome inhibitors, 2 immunomodulatory agents, and an anti-CD38 monoclonal antibody, and have experienced progressive disease on their last therapy.

Nikhil C. Munshi, MD, discusses the FDA approval of idecabtagene vicleucel for patients with relapsed/refractory multiple myeloma after 4 or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.

The FDA has approved idecabtagene vicleucel as the first BCMA-directed CAR T-cell therapy for patients with relapsed/refractory multiple myeloma after 4 or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.

Jesus G. Berdeja, MD, director of Myeloma Research, principal investigator, Sarah Cannon Research Institute, discusses the FDA approval of the chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed/refractory multiple myeloma.

Ola Landgren, MD, PhD, discusses the importance of understanding progressive vs stable multiple myeloma precursor conditions.

Nina Shah, MD, discusses the potential rationale for selecting between the investigational CAR T-cell therapies idecabtagene vicleucel and ciltacabtagene autoleucel in relapsed/refractory multiple myeloma.

Kenneth C. Anderson, MD, discusses potentially addressing unmet needs in patients with multiple myeloma through the use of the mRNA-based CAR T-cell therapy Descartes-11.

Saad Z. Usmani, MD, FACP, discusses future research directions with the combination of nirogacestat and teclistamab in patients with relapsed/refractory multiple myeloma.

Thomas G. Martin, MD, discusses factors that can inform transplant eligibility in multiple myeloma.

QIAGEN and INOVIO Pharmaceuticals, Inc. are extending their collaborative efforts with a new agreement to develop liquid biopsy–based companion diagnostic assays for INOVIO agents, according to a news release from INOVIO.

The addition of daratumumab to lenalidomide and dexamethasone resulted in improved progression-free survival vs Rd alone in patients with newly diagnosed multiple myeloma who were not eligible for transplant—even in frail patients.

Ciltacabtagene autoleucel has a manageable safety profile at its recommended phase 2 dose, and yielded early, deep, and durable responses in heavily pretreated patients with relapsed/refractory multiple myeloma.

Nicolaus Kröger, MD, discusses the long-term results of a phase 2 study in multiple myeloma.

Thomas G. Martin, MD, discusses the utility of aggressive frontline treatment in multiple myeloma.

Shaji K. Kumar, MD, discusses the challenges of selecting therapy for patients with heavily pretreated multiple myeloma.

Paul G. Richardson, MD, discusses the toxicity profile of melphalan flufenamide in relapsed/refractory multiple myeloma.